CRMD - CorMedix, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
8.29
-0.16 (-1.89%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close8.45
Open8.44
Bid8.20 x 1800
Ask8.28 x 1000
Day's Range8.23 - 8.60
52 Week Range0.85 - 13.70
Volume422,454
Avg. Volume1,908,340
Market Cap197.144M
Beta (3Y Monthly)2.56
PE Ratio (TTM)N/A
EPS (TTM)-1.51
Earnings DateMar 18, 2019 - Mar 22, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.00
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    CorMedix Completes Sale of $5.4 Million of NOL Tax Benefits Through New Jersey Economic Development Authority Program

    CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has completed the previously announced sale of $5.4 million of NOL tax benefits to two unrelated, profitable New Jersey corporations through the New Jersey Economic Development Authority’s New Jersey Technology Business Tax Certificate Transfer program for State Fiscal Year 2018. “We are pleased to have closed on this transaction,” said Khoso Baluch, CorMedix CEO. The New Jersey Technology Business Tax Certificate Transfer (NOL) program enables qualified, unprofitable NJ-based technology or biotechnology companies with fewer than 225 U.S. employees (including parent company and all subsidiaries) to sell a percentage of net operating losses and research and development (R&D) tax credits to unrelated profitable corporations.

  • ACCESSWIRE9 days ago

    CorMedix Notified of Compliance with NYSE American Listing Requirements

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / April 11, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that on Friday, April 5, 2019, the NYSE American notified CorMedix that the company had regained compliance with the NYSE American listing requirements because the company has resolved the continued listing deficiency with respect to Section 1003(a)(i), Section 1003(a)(ii) and Section 1003(a)(iii) of the NYSE American Company Guide.

  • Is CorMedix, Inc. (NYSEMKT:CRMD) Overpaying Its CEO?
    Simply Wall St.18 days ago

    Is CorMedix, Inc. (NYSEMKT:CRMD) Overpaying Its CEO?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! In 2016 Khoso Baluch was appointed CEO of CorMedix, Inc. (NYSEMKT:CRMD). This analysis aims first to contrast CEO...

  • Benzinga25 days ago

    The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 25) Axsome Therapeutics Inc (NASDAQ: AXSM ) Catalyst Pharmaceuticals ...

  • ACCESSWIRE26 days ago

    CorMedix Confirms Previously Announced One-For-Five Reverse Stock Split

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 25, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today confirmed that the previously announced one-for-five reverse stock split of the Company's common stock, par value $0.001, will be effective at 9:00 am Eastern Time tomorrow, March 26. The Company's common stock will trade on the NYSE American on a split-adjusted basis under a new CUSIP number, 21900C308, beginning on March 26, 2019. Khoso Baluch, CorMedix CEO commented, "We are implementing the reverse stock split as planned so that we have flexibility to take advantage of future investment opportunities, to possibly attract more institutional interest into our stock, and given our need to have available unissued shares to reserve for past transactions.

  • ACCESSWIRElast month

    CorMedix Inc. Announces Appointment of Phoebe Mounts as Executive Vice President and General Counsel

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 21, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the appointment of Dr. Phoebe Mounts, Esq. Dr. Mounts, currently a partner at the law firm Morgan Lewis, will head up the Company's legal, compliance and regulatory affairs.

  • ACCESSWIRElast month

    CorMedix Inc. Reports Fourth Quarter And Full-Year 2018 Financial Results, Announces Reverse Stock Split And Provides Business Update

    Conference Call Scheduled for Today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 14, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing ...

  • ACCESSWIRElast month

    CorMedix Inc. to Present at Roth and Oppenheimer & Co. Investor Conferences

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 11, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

  • Will CorMedix (CRMD) Report Negative Q4 Earnings? What You Should Know
    Zackslast month

    Will CorMedix (CRMD) Report Negative Q4 Earnings? What You Should Know

    CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • ACCESSWIRElast month

    CorMedix Inc. to Report Year Ended December 31, 2018 Financial Results on Thursday, March 14

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 7, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

  • ACCESSWIRE2 months ago

    CorMedix Inc. Appoints Alan W. Dunton, M.D. to Board of Directors

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 4, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that Alan W. Dunton, M.D. has been appointed unanimously to the Company's Board of Directors. Dr. Dunton becomes the sixth member of the Company's Board, filling a vacant seat previously occupied by Gary Gelbfish, M.D., who resigned in January 2019. Khoso Baluch, CorMedix Chief Executive Officer stated, "I am excited to have Alan join the board of CorMedix.

  • GlobeNewswire2 months ago

    Research Report Identifies SS&C Technologies, Allergan plc, CorMedix, The Allstate, Vedanta, and Lexicon Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Feb. 21, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE2 months ago

    Biotech Bounce Just Getting Started

    HENDERSON, NV / ACCESSWIRE / February 20, 2019 / Biotech may have had a hard 2018, but the sector is making up for lost time at the start of this year. This may be just getting started as many fund managers ...

  • Here's Why CorMedix Dropped as Much as 27.1% Today
    Motley Fool2 months ago

    Here's Why CorMedix Dropped as Much as 27.1% Today

    The company announced an update after meeting the FDA.

  • ACCESSWIRE2 months ago

    CorMedix Inc. Announces FDA Meeting Update

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / February 14, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has begun discussions with the U.S. FDA regarding its recently completed and unblinded Phase 3 LOCK-IT-100 study to support regulatory approval for Neutrolin®, the Company's investigational product under development as a catheter lock solution for patients suffering from end stage renal disease undergoing hemodialysis. At the meeting, the FDA agreed that the Company could request consideration of Neutrolin for approval under the LPAD (Limited Population Pathway for Antibacterial and Antifungal Drugs) pathway. Data originally submitted to the FDA included preliminary analyses from 653 subjects at the time of the interim analysis, including the first 28 cases of catheter-related blood stream infection (CRBSI).

  • ACCESSWIRE2 months ago

    Biotech and Cannabis Stocks That Are Emerging

    HENDERSON, NV / ACCESSWIRE / February 13, 2019 / One you should research right away, BioRestorative Therapies, Inc. (BRTX) , a life sciences company focused on stem cell-based therapies, is developing ...

  • ACCESSWIRE2 months ago

    These Healthcare Stocks Could Surpass Investor Expectations

    Companies working in the healthcare sector are tasked with meeting the growing demand for effective treatment options given that, almost every day, medical experts discover a new disease or ailment. Premier Health Group (OTC:PHGRF) (CSE:PHGI), CAS Medical Systems Inc (CASM), CorMedix Inc (NYSE American: CRMD), and Viking Therapeutics Inc (VKTX) represent four healthcare companies determined to create products to help consumers have a better life.

  • ACCESSWIRE3 months ago

    Cormedix Inc. Announces Topline Analysis of the Full Data Set of Phase 3 Lock-It-100 Study Reinforces the Interim Results

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / January 30, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the topline results of the full data set of the Company's Phase 3 LOCK-IT-100 study for Neutrolin® as a catheter lock solution in hemodialysis patients. The Company recently announced the topline results from the interim analysis of the study, which was terminated in August 2018 following the recommendation of the independent Data Safety Monitoring Board (DSMB), because efficacy had been demonstrated and the pre-specified level of statistical significance had been achieved. Efficacy data were available from 653 subjects at the time of the interim analysis, including the first 28 cases of catheter-related blood stream infection (CRBSI).

  • GlobeNewswire3 months ago

    Factors of Influence in 2019, Key Indicators and Opportunity within The Hain Celestial Group, Allegheny Technologies, NVR, Greif, CorMedix, and Enzo Biochem — New Research Emphasizes Economic Growth

    NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Options Traders Expect Huge Moves in CorMedix (CRMD) Stock
    Zacks3 months ago

    Options Traders Expect Huge Moves in CorMedix (CRMD) Stock

    Investors need to pay close attention to CorMedix (CRMD) stock based on the movements in the options market lately.

  • ACCESSWIRE3 months ago

    These 4 Healthcare Stocks Are Raising Expectations

    With the rise of global population, coupled with depletion of most common resources, consumer access to healthcare is crucial to securing the health and wellness of all living people, resulting in a need for companies in the space to meet these demands. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), LM Funding America Inc., (LMFA), CorMedix Inc (CRMD), and ContraFect Corp (CFRX) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients.

  • ACCESSWIRE3 months ago

    Cormedix Inc. Announces Highly Statistically Significant Topline Results For Neutrolin(R) From The Interim Analysis Of The Phase 3 Lock-It-100 Study

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / January 17, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the topline results of the interim analysis of the Company's Phase 3 LOCK-IT-100 study for Neutrolin® as a catheter lock solution in hemodialysis patients. As previously announced, the study was terminated at the recommendation of the independent Data Safety Monitoring Board (DSMB) after the interim analysis was completed in July 2018, because efficacy had been demonstrated and the pre-specified level of statistical significance had been achieved.

  • ACCESSWIRE3 months ago

    CorMedix Inc. Announces Resignation of Member of Its Board of Directors

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / January 16, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that Gary A. Gelbfish, MD FACS has resigned his position as a member of the Board of Directors, effective January 14, 2019.Dr. Gelbfish's most recent tenure on the board began in August 2017.He previously served on CorMedix's Board from December 2009 to June 2014, including a term as Board Chairman from 2012 to June 2014. Khoso Baluch, CorMedix Chief Executive Officer and a member of the Board stated, "We thank Gary for his service and guidance during the LOCK-IT-100 study.He provided significant insight that contributed to its successful completion.

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: Incyte and CorMedix

    NEW YORK, NY / ACCESSWIRE / January 16, 2019 /U.S. markets rose on Tuesday as Netflix helped push the tech sector higher after announcing it would raise the price of its monthly membership. Tech giants ...

  • ACCESSWIRE3 months ago

    This Stock Generated 25X Returns In Just Five Years: Could BTCY Be At The Same Crossroads?

    The move to get patients out of doctors offices and hospitals quickly using virtual care and remote monitoring is underway. Technology is enabling the switch, and few subsectors have benefitted more than remote cardiac care. Companies like Biotelemetry (BEAT) have grown by leaps and bounds in the last few years as their proprietary remote cardiac monitoring devices have gained traction.